BiotechTube
Home/Pipeline/Presbyopia Treatment

Presbyopia Treatment

Presbyopia

NDA SubmittedActive

Key Facts

Indication
Presbyopia
Phase
NDA Submitted
Status
Active
Company
Viatris (2)

About Viatris (2)

Viatris is a global healthcare leader with a mission to empower people worldwide to live healthier at every stage of life by ensuring reliable access to essential medicines. Its strategy leverages unparalleled scale, geographic reach, and operational excellence across development, manufacturing, and commercialization. The company is executing a strategic transformation, divesting non-core assets to strengthen its financial profile while investing in key growth areas like complex generics, biosimilars, and novel products to drive sustainable revenue and earnings growth through 2030.

View full company profile

Therapeutic Areas

CardiovascularCentral Nervous SystemInfectious DiseasesOncologyImmunologyOphthalmologyWomen's Health

Other Presbyopia Drugs

DrugCompanyPhase
Presbyopia-Correcting ICLSTAAR SurgicalResearch & Development
LB-01Lento BioDiscovery/IND-Enabling
LB-02Lento BioDiscovery
Presbyopia-Correcting Contact LensesClerio VisionDevelopment
Intra-corneal ImplantMAG OpticsPre-clinical
NVK029VylumaPhase 2
ArtiPlusOphtecClinical Trials
BRIMOCHOL™ PFTenpoint TherapeuticsNDA Submitted
Qlosi™Orasis PharmaceuticalsApproved
TSH‑001TSH BiopharmPhase 1/2
DE-128ASanten PharmaceuticalPhase 2
YP-10ViatrisNDA Filed